This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Merck & Co.’s cancer immunotherapy Keytruda is one of ...
“PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of ...
LOS ANGELES -- Patients with metastatic melanoma have faced grim prospects: the American cancer society says the five-year survival rate is only 15 percent. That started changing when the FDA approved ...
The U.S. Food and Drug Administration (FDA) on Friday approved Merck & Co Inc.’s (NYSE:MRK) Keytruda (pembrolizumab) for adult patients with resectable locally advanced head and neck squamous cell ...
A Merck sign hangs on the side of an office building in South San Francisco, California. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our ...
Merck & Co., Inc. (NYSE:MRK) is a leading global healthcare company that produces medicines for a variety of medical conditions, including cancer, infections, and chronic diseases. It is one of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback